痰热清注射液辅助治疗放射性肺炎的有效性及安全性评价

Th e Efficacy and Safety of Tanreqing Injection in Adjuvant Treatment for Radiation Pneumonitis:A Meta-analysis

目的系统评价痰热清注射液辅助治疗放射性肺炎的有效性与安全性。方法系统检索CBM、CNKI、维普、万方、Pubmed及Embase数据库,采用Cochrane协作网RCT质量评价标准评价纳入研究质量,Meta分析提取数据。结果 1)纳入9个RCT,放射性肺炎582例,纳入研究质量一般;2)Meta分析合并RR值包括临床显效[RR=1.35,95%CI(1.09,1.66)]、临床无效[RR=0.30,95%CI(0.18,0.48)]及总体疗效[RR=1.16,95%CI(1.05,1.28)](P<0.05);临床痊愈[RR=1.71,95%CI(1.28,2.30)]及临床有效[RR=0.87,95%CI(0.65,1.17)](P=0.36)。3)纳入1个研究均报道轻微不良反应。结论本研究表明痰热清注射液辅助治疗放射性肺炎的临床疗效优于抗生素联合激素,但存在轻微不良反应。纳入研究质量一般,建议临床慎用。

Objective： To systematically review the efficacy and safety of Tanreqing Injection in adjuvant treat- ment for radiation pneumonitis. Methods： All related studies were retrieved in CBM,CNKI,VIP,Wanfang, Pubmed and Embase;the quality of all included studies were evaluated by Cochrane scale and all data was ana- lyzed by meta-analysis. Results： 1 ）Nine RCTs involving 582 patients with radiation pneumonitis were included, with general methodological quality in most trials. 2）The merged RR values and their 95% CI of Meta-analysis for clinical marked effectiveness,and clinical failure and overall effect were as follows： 1.35 （1.09,1.66）,0.30 （0.18,0.48）and1.16 （1.05,1.28）and these were statistically significant. The clinical cure and clinical effective- ness were as follows： 1.34（0.93,1.93）and 0.87 （0.65,1.17）,which was not statistically significant.3）One studies reported the light adverse reaction. Conclusion： Our study shows that the clinical efficacy of Tanreqing Injection in adjuvant treatment is better than that of the antibiotic and glucocorticoid to radiation pneumonitis with light ad- verse reaction. But the quality of all studies is not high. Therefore ,we recommend careful application of Tanreqing Injection in clinical therapy.